10:34 AM EDT, 09/03/2025 (MT Newswires) -- Lantern Pharma ( LTRN ) said Wednesday that it concluded a meeting with the US Food and Drug Administration that provided guidance on a regulatory pathway for its planned pediatric study focused on central nervous system cancers, or CNS cancers, including atypical teratoid rhabdoid tumor.

The oncology company said it received feedback on its proposed trial structure, including a parallel cohort specifically for ATRT patients.

Lantern said the FDA allowed for the assessment of spironolactone's synergistic effects with the company's LP-184/STAR-001 therapy candidate in enhancing the potential efficacy in CNS cancers.

The company said it is now planning an investigational new drug application amendment for its LP-184/STAR-001 therapy candidate under its Starlight Therapeutics subsidiary.

Price: 4.01, Change: -0.02, Percent Change: -0.45